PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer.
PD-L1
biomarker
extracellular vesicles
immunotherapy
lung cancer
Journal
Journal of extracellular vesicles
ISSN: 2001-3078
Titre abrégé: J Extracell Vesicles
Pays: United States
ID NLM: 101610479
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
24
10
2023
received:
31
03
2023
accepted:
07
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
7
3
2024
Statut:
ppublish
Résumé
Immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer (NSCLC). High expression of tissue PD-L1 (tPD-L1) is currently the only approved biomarker for predicting treatment response. However, even tPD-L1 low (1-49%) and absent (<1%) patients might benefit from immunotherapy but, to date, there is no reliable biomarker, that can predict response in this particular patient subgroup. This study aimed to test whether tumour-associated extracellular vesicles (EVs) could fill this gap. Using NSCLC cell lines, we identified a panel of tumour-related antigens that were enriched on large EVs (lEVs) compared to smaller EVs. The levels of lEVs carrying these antigens were significantly elevated in plasma of NSCLC patients (n = 108) and discriminated them from controls (n = 77). Among the tested antigens, we focused on programmed cell death ligand 1 (PD-L1), which is a well-known direct target for immunotherapy. In plasma lEVs, PD-L1 was mainly found on a population of CD45
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12418Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : MyPathSem (031L0024A)
Organisme : Deutsche Forschungsgemeinschaft
ID : 424252458
Organisme : Novartis Pharma
ID : InCa Förderpreis 2021
Organisme : Else Kröner-Fresenius-Stiftung
ID : 2019_A162
Organisme : Innovative medical research (IMF) of the Medical Faculty, University of Münster
ID : ME121914
Informations de copyright
© 2024 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles.
Références
Ahmed, Y., Berenguer-Pina, J. J., & Mahgoub, T. (2021). The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon. Oncology, 99, 673-680.
Alique, M., Ruíz-Torres, M. P., Bodega, G., Noci, M. V., Troyano, N., Bohórquez, L., Luna, C., Luque, R., Carmona, A., Carracedo, J., & Ramírez, R. (2017). Microvesicles from the plasma of elderly subjects and from senescent endothelial cells promote vascular calcification. Aging, 9, 778-789.
Anderson, W., Kozak, D., Coleman, V. A., Jämting, Å. K., & Trau, M. (2013). A comparative study of submicron particle sizing platforms: Accuracy, precision and resolution analysis of polydisperse particle size distributions. Journal of Colloid and Interface Science, 405, 322-330.
Arendt, B. K., Walters, D. K., Wu, X., Tschumper, R. C., & Jelinek, D. F. (2014). Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget, 5, 5686-5699.
Ayers, L., Nieuwland, R., Kohler, M., Kraenkel, N., Ferry, B., & Leeson, P. (2015). Dynamic microvesicle release and clearance within the cardiovascular system: triggers and mechanisms. Clinical Science (Lond), 129, 915-931.
Ben Dori, S., Aizic, A., Sabo, E., & Hershkovitz, D. (2020). Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer. Lung Cancer, 147, 91-98.
Brennan, K., Martin, K., FitzGerald, S. P., O'Sullivan, J., Wu, Y., Blanco, A., Richardson, C., & Mc Gee, M. M. (2020). A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Scientific Reports, 10, 1039.
Castellana, D., Zobairi, F., Martinez, M. C., Panaro, M. A., Mitolo, V., Freyssinet, J.-M., & Kunzelmann, C. (2009). Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: A role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Research, 69, 785-793.
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., Xia, H., Man, Q., Zhong, W., Antelo, L. F., Wu, B., Xiong, X., Liu, X., Guan, L., Li, T., … Chen, Y. H. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 560, 382-386.
Choi, B. H., Quan, Y. H., Rho, J., Hong, S., Park, Y., Choi, Y., Park, J.-H., Yong, H. S., Han, K. N., Choi, Y. H., & Kim, H. K. (2020). Levels of extracellular vesicles in pulmonary and peripheral blood correlate with stages of lung cancer patients. World Journal of Surgery, 44, 3522-3529.
Ciardiello, C., Leone, A., Lanuti, P., Roca, M. S., Moccia, T., Minciacchi, V. R., Minopoli, M., Gigantino, V., De Cecio, R., Rippa, M., Petti, L., Capone, F., Vitagliano, C., Milone, M. R., Pucci, B., Lombardi, R., Iannelli, F., Di Gennaro, E., Bruzzese, F., … Budillon, A. (2019). Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. Journal of Experimental & Clinical Cancer Research, 38, 317.
Comfort, N., Cai, K., Bloomquist, T. R., Strait, M. D., Ferrante, A. W., & Baccarelli, A. A. (2021). Nanoparticle tracking analysis for the quantification and size determination of extracellular vesicles. Journal of Visualized Experiments, 169, e62447. https://doi.org/10.3791/62447
Cordonnier, M., Nardin, C., Chanteloup, G., Derangere, V., Algros, M.-P., Arnould, L., Garrido, C., Aubin, F., & Gobbo, J. (2020). Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. Journal of Extracellular Vesicles, 9, 1710899.
Coppinger, J. A., Cagney, G., Toomey, S., Kislinger, T., Belton, O., McRedmond, J. P., Cahill, D. J., Emili, A., Fitzgerald, D. J., & Maguire, P. B. (2004). Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood, 103, 2096-2104.
Darga, E. P., Dolce, E. M., Fang, F., Kidwell, K. M., Gersch, C. L., Kregel, S., Thomas, D. G., Gill, A., Brown, M. E., Gross, S., Connelly, M., Holinstat, M., Cobain, E. F., Rae, J. M., Hayes, D. F., & Paoletti, C. (2021). PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One, 16, e0260124.
Del Re, M., Marconcini, R., Pasquini, G., Rofi, E., Vivaldi, C., Bloise, F., Restante, G., Arrigoni, E., Caparello, C., Bianco, M. G., Crucitta, S., Petrini, I., Vasile, E., Falcone, A., & Danesi, R. (2018). PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. British Journal of Cancer, 118, 820-824.
de Miguel-Perez, D., Russo, A., Arrieta, O., Ak, M., Barron, F., Gunasekaran, M., Mamindla, P., Lara-Mejia, L., Peterson, C. B., Er, M. E., Peddagangireddy, V., Buemi, F., Cooper, B., Manca, P., Lapidus, R. G., Hsia, R.-C., Cardona, A. F., Naing, A., Kaushal, S., …, Rolfo, C. (2022). Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research, 41, 186.
D'Incecco, A., Andreozzi, M., Ludovini, V., Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., Chella, A., Fontanini, G., Filice, M. E., Tornillo, L., Incensati, R. M., Sani, S., Crinò, L., Terracciano, L., & Cappuzzo, F. (2015). PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer, 112, 95-102.
Dum, D., Taherpour, N., Menz, A., Höflmayer, D., Völkel, C., Hinsch, A., Gorbokon, N., Lennartz, M., Hube-Magg, C., Fraune, C., Bernreuther, C., Lebok, P., Clauditz, T. S., Jacobsen, F., Sauter, G., Uhlig, R., Wilczak, W., Steurer, S., Minner, S., …, Luebke, A. M. (2022). Trophoblast cell surface antigen 2 expression in human tumors: A tissue microarray study on 18,563 tumors. Pathobiology, 89, 245-258.
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45, 228-247.
Fleitas, T., Martínez-Sales, V., Vila, V., Reganon, E., Mesado, D., Martín, M., Gómez-Codina, J., Montalar, J., & Reynés, G. (2012). Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One, 7, e47365.
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., Cheng, S. Y.-S., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Boyer, M., … Garassino, M. C. (2018). KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. The New England Journal of Medicine, 378, 2078-2092.
Gardiner, C., Ferreira, Y. J., Dragovic, R. A., Redman, C. W. G., & Sargent, I. L. (2013). Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. Journal of Extracellular Vesicles, 2, 19671.
Guibert, N., Delaunay, M., Lusque, A., Boubekeur, N., Rouquette, I., Clermont, E., Mourlanette, J., Gouin, S., Dormoy, I., Favre, G., Mazieres, J., & Pradines, A. (2018). PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer, 120, 108-112.
Han, Y., Liu, D., & Li, L. (2020). PD-1/PD-L1 pathway: Current researches in cancer. American Journal of Cancer Research, 10, 727-742.
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., Scheuermann, S., Horger, M., Maurer, S., Walz, J., Fend, F., Handgretinger, R., Seitz, C., Weigelin, B., Singer, S., …, Zender, L. (2021). Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature Communications, 12, 7005.
Ilié, M., Szafer-Glusman, E., Hofman, V., Chamorey, E., Lalvée, S., Selva, E., Leroy, S., Marquette, C.-H., Kowanetz, M., Hedge, P., Punnoose, E., & Hofman, P. (2018). Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Annals of Oncology, 29, 193-199.
Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., Yang, C.-T., Araujo, L. H., Saito, H., Reinmuth, N., Shi, X., Poole, L., Peters, S., Garon, E. B., Mok, T., & investigators, P. (2022). Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. Journal of Clinical Oncology, 41(6), JCO2200975.
Kalluri, R. (2016). The biology and function of exosomes in cancer. Journal of Clinical Investigation, 126, 1208-1215.
Kim, S. J., Rabbani, Z. N., Vollmer, R. T., Schreiber, E.-G., Oosterwijk, E., Dewhirst, M. W., Vujaskovic, Z., & Kelley, M. J. (2004). Carbonic anhydrase ix in early-stage non-small cell lung cancer. Clinical Cancer Research, 10, 7925-7933.
Kim, D. H., Kim, H., Choi, Y. J., Kim, S. Y., Lee, J.-E., Sung, K. J., Sung, Y. H., Pack, C.-G., Jung, M.-K., Han, B., Kim, K., Kim, W. S., Nam, S. J., Choi, C.-M., Yun, M., Lee, J. C., & Rho, J. K. (2019). Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Experimental & Molecular Medicine, 51, 1-13.
Kluger, H. M., Zito, C. R., Turcu, G., Baine, M. K., Zhang, H., Adeniran, A., Sznol, M., Rimm, D. L., Kluger, Y., Chen, L., Cohen, J. V., & Jilaveanu, L. B. (2017). PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors. Clinical Cancer Research, 23, 4270-4279.
Lacroix, R., Judicone, C., Poncelet, P., Robert, S., Arnaud, L., Sampol, J., & Dignat-george, F. (2012). Impact of pre-analytical parameters on the measurement of circulating microparticles: Towards standardization of protocol. Journal of Thrombosis and Haemostasis, 10, 437-446.
Langer, C., Gadgeel, S., Borghaei, H., Patnaik, A., Powell, S., Gentzler, R., Yang, J. C., Gubens, M., Sequist, L., Awad, M., Cristescu, R., Aurora-Garg, D., Albright, A., Loboda, A., Kobie, J., Lunceford, J., Ayers, M., Lubiniecki, G., Piperdi, B., … Papadimitrakopoulou, V. (2019). OA04.05 KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC. Journal of Thoracic Oncology, 14, S216.
Li, C., Li, C., Zhi, C., Liang, W., Wang, X., Chen, X., Lv, T., Shen, Q., Song, Y., Lin, D., & Liu, H. (2019). Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. Journal of Translational Medicine, 17, 355.
Lin, J.-C., Wu, Y.-Y., Wu, J.-Y., Lin, T.-C., Wu, C.-T., Chang, Y.-L., Jou, Y.-S., Hong, T.-M, & Yang, P.-C. (2012). TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Molecular Medicine, 4, 472-485.
Lischnig, A., Bergqvist, M., Ochiya, T., & Lässer, C. (2022). Quantitative proteomics identifies proteins enriched in large and small extracellular vesicles. Molecular & Cellular Proteomics, 21, 100273.
Lobb, R. J., Visan, K. S., Wu, L.-Y., Norris, E. L., Hastie, M. L., Everitt, S., Yang, I. A., Bowman, R. V., Siva, S., Larsen, J. E., Gorman, J. J., MacManus, M., Leimgruber, A., Fong, K. M., & Möller, A. (2023). An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer. Communications Biology, 6, 1-9.
Maramotti, S., Paci, M., Manzotti, G., Rapicetta, C., Gugnoni, M., Galeone, C., Cesario, A., & Lococo, F. (2016). Soluble epidermal growth factor receptors (sEGFRs) in cancer: Biological aspects and clinical relevance. International Journal of Molecular Sciences, 17, 593.
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., Ueno, N. T., Litton, J. K., Ferrarotto, R., Chang, J. T., Moulder, S. L., & Lin, S.-Y. (2021). High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology, 32, 661-672.
Menck, K., Scharf, C., Bleckmann, A., Dyck, L., Rost, U., Wenzel, D., Dhople, V. M., Siam, L., Pukrop, T., Binder, C., & Klemm, F. (2015). Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN. Journal of Molecular Cell Biology, 7, 143-153.
Menck, K., Klemm, F., Gross, J. C., Pukrop, T., Wenzel, D., & Binder, C. (2013). Induction and transport of Wnt 5a during macrophage-induced malignant invasion is mediated by two types of extracellular vesicles. Oncotarget, 4, 2057-2066.
Menck, K., Bleckmann, A., Wachter, A., Hennies, B., Ries, L., Schulz, M., Balkenhol, M., Pukrop, T., Schatlo, B., Rost, U., Wenzel, D., Klemm, F., & Binder, C. (2017). Characterisation of tumour-derived microvesicles in cancer patients’ blood and correlation with clinical outcome. Journal of Extracellular Vesicles, 6, 1340745.
Menck, K., Heinrichs, S., Baden, C., & Bleckmann, A. (2021). The WNT/ROR pathway in cancer: From signaling to therapeutic intervention. Cells, 10, 142.
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Salman, P., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., … Reck, M. (2021). First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. Lancet Oncology, 22, 198-211.
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., …, Kowalski, D. M. (2018). KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. The New England Journal of Medicine, 379, 2040-2051.
Pfeiler, S., Thakur, M., Grünauer, P., Megens, R. T. A., Joshi, U., Coletti, R., Samara, V., Müller-Stoy, G., Ishikawa-Ankerhold, H., Stark, K., Klingl, A., Fröhlich, T., Arnold, G. J., Wörmann, S., Bruns, C. J., Algül, H., Weber, C., Massberg, S., & Engelmann, B. (2019). CD36-triggered cell invasion and persistent tissue colonization by tumor microvesicles during metastasis. The FASEB Journal, 33, 1860-1872.
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., & Blelloch, R. (2019). Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell, 177, 414-427.e13.
Rolfes, V., Idel, C., Pries, R., Plötze-Martin, K., Habermann, J., Gemoll, T., Bohnet, S., Latz, E., Ribbat-Idel, J., Franklin, B. S., & Wollenberg, B. (2018). PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget, 9, 27460-27470.
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R. (2016). KEYNOTE-024 investigators. pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. The New England Journal of Medicine, 375, 1823-1833.
Serratì, S., Guida, M., Di Fonte, R., De Summa, S., Strippoli, S., Iacobazzi, R. M., Quarta, A., De Risi, I., Guida, G., Paradiso, A., Porcelli, L., & Azzariti, A. (2022). Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Molecular Cancer, 21, 20.
Shen, X., & Zhao, B. (2018). Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ, 362, k3529.
Signorelli, D., Ghidotti, P., Proto, C., Brambilla, M., De Toma, A., Ferrara, R., Galli, G., Ganzinelli, M., Lo Russo, G., Prelaj, A., Occhipinti, M., Viscardi, G., Capizzuto, V., Pontis, F., Petraroia, I., Ferretti, A. M., Colombo, M. P., Torri, V., …, Fortunato, O. (2020). Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. Frontiers in Immunology, 13, 987639.
Stepan, L. P., Trueblood, E. S., Hale, K., Babcook, J., Borges, L., & Sutherland, C. L. (2011). Expression of Trop2 cell surface glycoprotein in normal and tumor tissues. Journal of Histochemistry and Cytochemistry, 59, 701-710.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
Timaner, M., Kotsofruk, R., Raviv, Z., Magidey, K., Shechter, D., Kan, T., Nevelsky, A., Daniel, S., de Vries, E. G. E., Zhang, T., Kaidar-Person, O., Kerbel, R. S., & Shaked, Y. (2020). Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. Oncogene, 39, 187-203.
Uruga, H., Bozkurtlar, E., Huynh, T. G., Muzikansky, A., Goto, Y., Gomez-Caraballo, M., Hata, A. N., Gainor, J. F., Mark, E. J., Engelman, J. A., Lanuti, M. D., & Mino-Kenudson, M. (2017). Programmed cell death ligand (PD-L1) expression in stage ii and iii lung adenocarcinomas and nodal metastases. Journal of Thoracic Oncology, 12, 458-466.
Van Deun, J., Mestdagh, P., Agostinis, P., Akay, Ö., Anand, S., Anckaert, J., Martinez, Z. A., Baetens, T., Beghein, E., Bertier, L., Berx, G., Boere, J., Boukouris, S., Bremer, M., Buschmann, D., Byrd, J. B., Casert, C., Cheng, L., Cmoch, A., …, Gärtner, K. (2017). EV-TRACK: Transparent reporting and centralizing knowledge in extracellular vesicle research. Nature Methods, 14, 228-232.
Van Deun, J., Mestdagh, P., Sormunen, R., Cocquyt, V., Vermaelen, K., Vandesompele, J., Bracke, M., De Wever, O., & Hendrix, A. (2014). The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. Journal of Extracellular Vesicles, 3, 24858.
van Niel, G., D'Angelo, G., & Raposo, G. (2018). Shedding light on the cell biology of extracellular vesicles. Nature Reviews Molecular Cell Biology, 19, 213-228.
Yang, Y., Li, C.-W., Chan, L.-C., Wei, Y., Hsu, J.-M., Xia, W., Cha, J.-H., Hou, J., Hsu, J. L., Sun, L., & Hung, M.-C. (2018). Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Research, 28, 862-864.
Yáñez-Mó, M., Siljander, P. R.-M., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., Colás, E., Cordeiro-da Silva, A., Fais, S., Falcon-Perez, J. M., Ghobrial, I. M., Giebel, B., Gimona, M., Graner, M., Gursel, I., … Lener, T. (2015). Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 4, 27066.
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016). PD-L1 expression in lung cancer. Journal of Thoracic Oncology, 11, 964-975.
Zamay, T. N., Zamay, G. S., Kolovskaya, O. S., Zukov, R. A., Petrova, M. M., Gargaun, A., Berezovski, M. V., & Kichkailo, A. S. (2017). Current and prospective protein biomarkers of lung cancer. Cancers, 9, 155.
Zhang, X., Tian, T., Zhang, X., Liu, C., & Fang, X. (2017). Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer. Oncotarget, 8, 37673-37680.